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Drug-induced liver injury (DILI) is an important cause of death and indication for liver transplantation (fatality). The role of
DILI in these fatalities is poorly characterized, particularly when fatalities occur >26 weeks after DILI onset. We analyzed
patients in the US Drug-Induced Liver Injury Network prospective study having a fatal outcome within 2 years of onset. Each
case was reviewed by eight network investigators and categorized as DILI having a primary, a contributory, or no role in the
fatality. We subcategorized primary role cases as acute, chronic, acute-on-chronic, or acute cholestatic liver failure. For contribu-
tory and no role cases, we assigned a primary cause of death. Among 1,089 patients, 107 (9.8%) fatalities occurred within 2 years.
DILI had a primary role in 68 (64%), a contributory role in 15 (14%), and no role in 22 (21%); 2 had insufficient data. Among
primary role cases, 74% had acute, 13% chronic, 7% acute on chronic, and 6% acute cholestatic failure. For the 15 contributory
role cases, common causes of death included sepsis, malignancy, and severe cutaneous reactions with multiorgan failure. For the
22 no role cases, malignancies accounted for most fatalities. Higher bilirubin, coagulopathy, leukocytosis, and thrombocytopenia
were independently associated with DILI fatalities. New R ratio Hy’s law had a higher positive predictive value for overall fatality
(14% versus 10%) and a stronger independent association with DILI fatalities within 26 weeks compared to the original version
of Hy’s law (hazard ratio, 6.2, 95% confidence interval 3.4-11.1, versus 2.2, 95% confidence interval 1.3-3.7). Conclusions: DILI
leads directly or indirectly to fatality in 7.6% of cases; 40% of these had nonacute liver failure courses. New R ratio Hy’s law bet-
ter identifies risk for death compared to the original Hy’s law. (HEPATOLOGY 2017;66:1275-1285).
Most patients suffering hepatotoxicity due tomedications or herbal or dietary supple-ments (HDS) recover from the acute liver
injury without long-term sequelae. However, a
proportion does not survive the injury or requires liver
transplantation (LT) (referred to hereafter as a death,
mortality, fatality or fatal outcome). Most large regis-
tries of drug-induced liver injury (DILI) report a
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mortality rate of approximately 10%.(1-3) However, the
contribution of DILI in these fatalities is not always
clear, particularly when they occur more than 26 weeks
after DILI onset. There are emerging data on chronic
or persistent DILI that continues beyond 6 or 12
months.(4-7) DILI may also contribute significantly to
a fatality without being the primary cause of death.
Such cases should be analyzed separately but counted
as part of DILI’s disease burden. Determining the con-
tribution of liver injury to a fatality can be difficult if
patient data are not collected prospectively and assessed
systematically. Lastly, accurate classification of DILI-
related fatalities allows more accurate analyses of pre-
dictors of death, such as Hy’s law and its derivations.
For these reasons, we performed a systematic analy-
sis of all patients who had a fatal outcome within 2
years of onset in the prospective study of the US Drug
Induced-Liver Injury Network (DILIN). In addition,
we categorized the DILI as playing a primary, a con-
tributory, or no role in the fatality. Using these catego-
ries of fatal outcomes, we assessed clinical variables
including Model for End-Stage Liver Disease
(MELD), Hy’s law, and its modified version using a
new R ratio (nR) proposed by Robles-Diaz et al.(8)
Patients and Methods
DESIGN
The design of the DILIN prospective study has been
described in detail.(9,10) Briefly, all patients suspected of
having idiosyncratic drug-induced or HDS-induced
liver injury were eligible if they could be enrolled within
6 months of onset of the injury and met specific criteria
of laboratory abnormalities. These included serum
alanine (ALT) or aspartate aminotransferase (AST) >5
3 upper limit of normal (ULN) (or pretreatment base-
line if abnormal) on two consecutive occasions, alkaline
phosphatase (Alk P) levels >23 ULN (or pretreatment
baseline if abnormal) on two consecutive occasions, or
total bilirubin at least 2.5 mg/dL or an international
normalized ratio (INR) >1.5 accompanied by any ele-
vation in AST, ALT, or Alk P. Acetaminophen over-
dose cases and cases with certain chronic liver diseases
such as autoimmune hepatitis and primary biliary cir-
rhosis were excluded. Subjects were asked to return 6
months after onset and, if laboratory or clinical abnor-
malities related to the liver injury were still present, to
return at 12 and 24 months. At enrollment, relevant
medical information was extracted from the medical
records and interim history, physical examination, and
appropriate laboratory results were obtained.
CAUSALITY ASSESSMENT
AND SEVERITY OF INJURY
The DILIN prospective study used a consensus
expert opinion method of causality assessment.(9,10) The
DILIN investigator who enrolled the patient and two
investigators from two other centers were provided with
a standardized clinical narrative and summary of rele-
vant clinical, laboratory, histologic, and imaging results.
The three investigators independently assigned a causal-
ity score representing percent likelihood of attribution,
in which 15 definite or >95% likelihood of DILI, 25
highly likely or 75%-95% likelihood, 3 5 probable or
50%-74%, 4 5 possible or 25%-49%, and 5 5 unlikely
or <25%. Consensus on scoring was reached by e-mails
and web-based conference calls which included all
DILIN investigators. Each case was also assigned a
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severity score of 1-5 (5 5 fatal or needing LT) based
on bilirubin, INR, hospitalization, need for LT, or
fatality.(2)
STUDY COHORT
We identified all cases enrolled in the DILIN bet-
ween September 2004 and April 2015 and scored as 1
(definite DILI), 2 (highly likely), or 3 (probable). We
then selected and analyzed all patients who died or
underwent LT during the 2-year period of follow-up.
For the purposes of this analysis, we refer to all these
cases as fatalities or deaths even though some survived
beyond LT.
CATEGORIZATION BY ROLE
OF DILI IN DEATH OR LT
Clinical death narratives and summaries of serial
clinical, laboratory, histologic, and imaging results
were prepared for each case of death or LT in the
DILIN prospective cohort study. A Death Review
Subcommittee consisting of eight DILIN hepatolo-
gists was established, and each case was assigned ran-
domly to two members for independent review. Each
reviewer subjectively categorized the cases for whether
the DILI episode played a primary, a contributory, or
no role in the death. We resolved discrepancies bet-
ween reviewers by conference call discussion that
included the entire Death Review Subcommittee. The
subcommittee had the prerogative to ask that any case
be sent back for full causality assessment described
above if, on review of the fatal outcome, the original
diagnosis of DILI was called into question.
PATTERN OF LIVER FAILURE
FOR PRIMARY ROLE CASES
Cases where DILI clearly played a primary role in
the death or transplant had to be subcategorized into
one of four mutually exclusive clinical patterns of fatal
liver failure:
1. Acute liver failure (ALF) deaths were defined as
acute liver insult with INR 1.5, hepatic enceph-
alopathy, no evidence of preexisting or underlying
advanced liver disease or cirrhosis, and death
occurring in less than 26 weeks.(11,12)
2. Acute-on-chronic liver failure (ACLF) deaths
were defined as acute liver insult with INR 1.5,
hepatic encephalopathy, clinical or histologic evi-
dence of preexisting advanced liver disease or
cirrhosis, and death occurring in less than 26
weeks.(13)
3. Acute cholestatic liver failure deaths had acute
injury with an R value <2, no preexisting liver
disease, no hepatic encephalopathy, and death
occurring in less than 26 weeks (i.e., acute chole-
static failure not meeting ALF criteria).
4. Chronic liver failure deaths were defined as acute
liver insult with consequent hepatic decompensa-
tion (e.g., ascites, jaundice, encephalopathy, coa-
gulopathy) with or without evidence of preexisting
liver disease and death occurring due to liver fail-
ure more than 26 weeks later.
CAUSE OF DEATH FOR
CONTRIBUTORY AND NO
ROLE CASES
Criteria used to categorize DILI as having a contrib-
utory role in the death included the following: (1)
DILI left the patient in a weakened or malnourished
state which contributed to death by another disease
(e.g., cancer), (2) DILI prevented necessary care (e.g.,
surgery or chemotherapy) of another fatal illness, (3)
DILI exacerbated or was part of another concurrent
fatal illness (e.g., sepsis, multiorgan failure, drug reac-
tion with eosinophilia and systemic symptoms
[DRESS]), and (4) the death was due to a complica-
tion from a test or procedure done to evaluate the
DILI (e.g., bowel perforation from an endoscopic ret-
rograde cholangiopancreatography).
No role cases lacked any of the above criteria and
often had recovered or nearly recovered from the DILI
when they died of another illness. Both contributory
and no role cases were then assigned 1 of 18 primary
causes of death (Supporting Table S1). We resolved
discrepancies between reviewers by conference call dis-
cussion that included the entire Death Review Sub-
committee of eight members.
DESCRIPTIVE DATA, CLINICAL
VARIABLES, AND ANALYSIS
Data analyzed included routine demographic, clini-
cal, and laboratory test results as well as time from
starting the implicated drug or HDS to onset of injury
and time from injury onset to death or LT. The pat-
tern of injury was categorized as hepatocellular, chole-
static, or mixed based upon the R ratio from laboratory
tests taken at the time of onset: R ratio 5 (ALT/
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ULN) 4 (Alk P/ULN). R ratios >5 were considered
hepatocellular, <2 were considered cholestatic, and
2-5 were considered mixed. We also classified cases
by Hy’s law and the nR Hy’s law criteria at
presentation:
1. Hy’s law: bilirubin 2.5 mg/dL, ALT >3 times
ULN and Alk P <2 times ULN
2. nR Hy’s law: bilirubin 2.5 mg/dL, and [(ALT/
ULN) 4 (Alk P/ULN)] > 5. (AST is substituted
for ALT if the AST yields a greater R ratio).(8)
Using these clinical variables, we described those
who survived compared to those who died or under-
went LT. We also compared primary, contributory, or
no role cases. We determined performance characteris-
tics for MELD, Hy’s law, and nR Hy’s law for identi-
fying mortality risk due primarily or partially to DILI
at 2 years and DILI-related ALF and ACLF on uni-
variate and multivariate analyses.
STATISTICAL ANALYSIS
Standard descriptive methods (e.g., mean, standard
deviation, median, quartiles, percentages) were used to
describe the total cohort and subgroups. Comparisons
between subgroups were performed using standard
parametric and nonparametric tests where appropriate.
We used Cox proportional hazard ratios to identify
clinical variables independently associated with overall
DILI-related deaths (primary or contributory role) at 2
years. We also determined the performance cha-
racteristics for MELD, Hy’s law, and nR Hy’s law
(e.g., positive predictive value, hazard ratios, C statis-
tic) in predicting deaths from DILI-related ALF and
ACLF.
ROLE OF FUNDING SOURCE
AND INSTITUTIONAL
REVIEW BOARD
The DILIN is structured as a U01 cooperative
agreement with funds provided by the National Insti-
tute of Diabetes and Digestive and Kidney Diseases.
Separate institutional review board approvals were
maintained at each DILIN center throughout the
period of this study, and protocols were approved and
all data monitored by a separate Data Safety and Mon-
itoring Board appointed by the National Institute of
Diabetes and Digestive and Kidney Diseases.
Results
SUBJECTS
As of April 10, 2015, a total of 1,509 patients were
enrolled in the DILIN prospective study, of whom
1,332 underwent formal causality assessment and
1,089 were judged to have definite, highly likely, or
probable DILI. Among these, 107 (9.8%) died or
underwent LT (all-cause mortalities) within 2 years of
onset (Fig. 1). The Death Review Subcommittee did
not send any of the 107 fatalities back for causality
reassessment.
Comparison of patients who survived with those
who died or underwent LT is shown in Table 1.
Patients with a fatal outcome were on average some-
what older than those who survived (mean 5 53.1 ver-
sus 48.5 years) but were similar in other demographic
aspects. Initial laboratory results showed higher levels
of ALT, AST, bilirubin, and INR in those with fatal
outcome; but the R ratio and distribution of patterns
of injury were similar. Fatalities had higher proportions
meeting Hy’s law and nR Hy’s law criteria, but only
the latter reached statistical significance.
CATEGORIES BY ROLE OF DILI
IN DEATH OR TRANSPLANT
DILI was considered to have a primary role in the
death or need for transplantation in 68 (64%) patients
(Fig. 1). DILI had a contributory role in 15 cases
(14%) and no role in 22 cases (21%). The role could
not be determined due to insufficient follow-up details
for 2 patients. The clinical and laboratory features
associated with the three categories are shown in Table
2. Patients in whom DILI was the primary cause of
death were younger and more likely female; had higher
levels of ALT, AST, bilirubin, INR, and R ratio; and
were more likely to have hepatocellular injury than no
role cases. Contributory role cases had features more
like no role cases, except for female sex, which was
similar to primary role cases. A higher proportion of
primary role cases met Hy’s law criteria (40.3%) com-
pared to contributory or no role cases, but the differ-
ence was statistically significant only when compared
to no role cases (Table 2). An even higher proportion
of primary role cases met nR Hy’s law (65.6%), and
this was statistically higher than either contributory or
no role cases. Listing and frequency of specific agents
are shown in Supporting Tables S2-S5.
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CLINICAL COURSE OF LIVER
FAILURE IN DILI PRIMARY
ROLE CASES
Clinical features of the patients in which DILI
played a primary role in the fatal outcome are shown in
Table 3, subcategorized by their clinical course of liver
failure. Of these 68 primary role cases, 50 (74%) had
ALF as shown by marked elevations in serum ALT
and AST levels with relatively mild increases in Alk P
and a median time to death or transplant of 24 days
(range 2-123 days). Another 5 (7%) patients had
ACLF with less marked increases in ALT and AST
(and AST > ALT). Time to death or transplant
ranged from 6 to 135 days. Nine patients (13%) had a
DILI-related chronic liver failure accompanied by
lower median values for ALT and AST and higher val-
ues for Alk P. For 7 of these 9, time from DILI onset
to death or transplant ranged from 217 to 410 days.
The other two had liver injury from methotrexate and
amiodarone, both known to cause gradual fibrosis
accumulation with only modest enzyme elevations.
Therefore, a precise onset of DILI for these agents was
indeterminable, but the exposure time for the amiodar-
one was 847 days and that for methotrexate, 2,129
days. Finally, 4 patients (6%) had a rapidly progressive
cholestatic course, resulting in liver failure and death in
3 and transplantation in 1. Death or transplant
occurred at 48-171 days of onset in these 4, who
tended to be older (ages 75, 65, 61, and 48 years).
ALF and ACLF cases had significantly higher propor-
tions meeting Hy’s law and nR Hy’s law criteria (40%-
79%) compared to relatively few patients meeting such
criteria in the chronic or acute cholestatic group (0%-
25%) (Table 3).
Gender, race, and ethnicity did not differ signifi-
cantly among the cases with different patterns of liver
failure, although those with typical ALF tended to be
younger (mean age 48.7 years) than patients with other
patterns. The percentage of LTs was low for ACLF (1
TABLE 1. Characteristics of Patients Dying or Requiring LT
Within 2 Years of DILI Onset (n 5 107) Compared to Those
Alive at 2 Years Without LT
Characteristic
Died/LT
Within 2 Years
Post-DILI
(n 5 107)
Alive at 2 Years
Post-DILI
(n 5 982) P
Mean age, years (SD) 53.1 (16.4) 48.5 (17.0) 0.01
Gender, female (%) 57 (53.3%) 577 (58.8%) 0.30
Mean BMI, kg/m2 (SD) 28.7 (6.82) 27.4 (6.81) 0.01
Race/ethnicity
White 76 (72%) 781 (80%) 0.10
Black 17(16%) 110/ (11%)
Asian 7(7%) 30 (3%)
Other and unknown 7/(7%) 62 (6%)
Latino 6 (6%) 110 (11%) 0.10
Alcohol use 48/104 (46%) 501 (52%) 0.30
Chronic liver disease 13/62 (21%) 144/866 (17%) 0.50
Liver biochemistries at DILI onset—mean (SD)
ALT, U/L 1,162 (1326) 787 (1064) 0.02
AST, U/L 1,093 (1199) 634 (993) <0.01
Alk P, U/L 281 (217) 280 (249) 0.36
Bilirubin, mg/dL 10.1 (8.0) 6.3 (6.3) <0.01
INR 2.2 (1.8) 1.3 (0.7) <0.01
R ratio* 14.9 (19.8) 12.7 (25.16) 0.43
Pattern of injury (102/925)
Hepatocellular 61 (60%) 497 (54%) 0.11
Mixed 15 (15%) 220 (24%)
Cholestatic 26 (26%) 208 (23%)
Causality category
Definite 16 (15%) 253 (25.8%) <0.01
Highly likely 45 (42%) 523 (53.3%)
Probable 46 (43%) 206 (21.0%)
Hy’s law† 34/101 (33.7%) 269/913 (29.5%) 0.42
nR Hy’s law‡ 50/103 (48.5%) 292/936 (31.2%) <0.01
*R ratio 5 (ALT/ULN) 4 (Alk P/ULN).
†Bilirubin 2.5 mg/dL, ALT > 3 3 ULN and Alk P < 2 3
ULN at presentation.
‡Bilirubin 2.5 mg/dL and R ratio >5 at presentation (AST
substituted for ALT if AST yields greater R ratio).(8)
Abbreviations: BMI, body mass index; SD, standard deviation.
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FIG. 1. Analysis of DILIN patients with definite, highly likely
or probable DILI. Patients dying or needing transplant catego-
rized by role of DILI. Patients where DILI had Primary Role
subcategorized by pattern of liver failure. Contributory and No
Role patients subcategorized by cause of death or transplant.
                                                                 
HEPATOLOGY, Vol. 66, No. 4, 2017 HAYASHI ET AL.
1279
of 5, 20%) and for acute cholestatic liver failure (1 of 4,
25%) and higher for chronic liver failure (5 of 9, 56%)
and ALF (34 of 50, 68%).
CAUSES OF DEATH IN
CONTRIBUTORY ROLE CASES
Of the 15 patients whose DILI was considered to
play a contributory role, the primary causes of death
were judged to be sepsis in 3, malignancy in 3, another
unrelated liver disease in 3 (nonalcoholic liver disease
in 1 and autoimmune hepatitis in 2), and severe cuta-
neous reaction with systemic complications in 3 (Fig.
2). In many situations, the role of the liver injury was
difficult to assess, the underlying comorbidities being
severe and potentially fatal on their own. In these sit-
uations, the episode of DILI was believed to hasten
the fatal outcome.
CAUSES OF DEATH IN NO
ROLE CASES
Of the 22 patients where DILI played no role in the
outcome, malignancies accounted for over half of cases
(12, 55%). The remaining patients died from a variety
of causes (Fig. 2).
TABLE 2. Comparison of Patients Dying or Requiring LT Within 2 Years of DILI Onset (n 5 105) by DILI Role in Death
or Need for LT
Characteristic
DILI Role in Death or Need of LT
(n 5 105)* P
Primary
(n 5 68)
Contributory
(n 5 15)
No role
(n 5 22)
Primary versus
Contributory
Primary versus
No Role
Mean age, years (SD) 50.7 (16.0) 58.9 (16.2) 57.9 (17.2) 0.06 0.08
Gender, female 42 (62%) 9 (60%) 6 (27%) 0.89 0.01
Mean BMI, kg/m2 (SD) 29.2 (6.7) 31.3 (9.1) 25.6 (4.8) 0.31 0.02
Race/ethnicity
White 46 (69%) 12 (80%) 17 (77%) 0.95 0.58
Black 11 (16%) 2 (13%) 3 (14%)
Asian 6 (9%) 1 (7%) 0 (0%)
Other 4 (6%) 0 (0%) 2 (9%)
Latino 5 (7%) 1 (7%) 0 (0.0%) 1.00 0.33
Alcohol use 35/66 (53%) 4/14 (29%) 9/22 (41%) 0.10 0.33
Chronic liver disease 11 (16%) 3 (20%) 6 (27%) 0.13 0.25
Liver biochemistries at DILI onset
ALT, U/L 1,470 (1483) 587 (694) 579 (740) 0.02 <0.01
AST, U/L 1,422 (1326) 503 (589) 446 (547) 0.01 <0.01
Alk P, U/L 252 (150) 343 (326) 331 (288) 0.34 0.66
Bilirubin, mg/dL 11 (7.5) 9.6 (8.8) 6.6 (7.5) 0.31 <0.01
INR 2.2 (1.0) 2.4 (2.1) 1.6 (0.9) 0.43 0.17
R ratio† 18.6 (22.4) 6.5 (6.6) 9.2 (15.5) 0.04 0.02
Pattern of injury
Hepatocellular 50 (74%) 6 (40%) 8 (36%) <0.01 0.01
Mixed 4 (6%) 6 (40%) 5 (23%)
Cholestatic 14 (21%) 3 (20%) 9 (41%)
Causality category
Definite 9 (13%) 1 (7%) 5 (23%) 0.61 0.23
Highly likely 26 (41%) 5 (33%) 11 (50%)
Probable 31(46%) 9 (60%) 6 (27%)
Hy’s law‡ 25/62(40.3%) 5/15 (33.3%) 3/22 (13.6%) 0.62 0.02
nR Hy’s law§ 42/64(65.6%) 5/15 (33.3%) 2/22 (9.1%) 0.02 <0.01
*DILI role could not be determined in 2 patients.
†R ratio 5 (ALT/ULN) 4 (Alk P/ULN).
‡Bilirubin 2.5 mg/dL, ALT >3 3 ULN and Alk P <2 3 ULN at presentation.
§Bilirubin 2.5 mg/dL and R ratio >5 at presentation (AST substituted for ALT if AST yields greater R ratio).
Abbreviations: BMI, body mass index; SD, standard deviation.
HAYASHI ET AL. HEPATOLOGY, October 2017
1280
SPECIFIC AGENTS LEADING
TO FATALITY
Specific agents and HDS products as a whole are
shown in frequency tables by role of DILI in the fatali-
ties (Supporting Tables S2-S5).
VARIABLES ASSOCIATED WITH
DEATH OR LT
We compared patients with DILI-related death or
LT (primary and contributory role patients, n 5 83) to
the rest of the cohort (survivors, no role cases, and
unknown role cases5 1,006) (Fig. 1). Variables associ-
ated with fatality due primarily or partially to DILI on
univariate and multivariate analyses are shown in Table
4. Higher bilirubin, higher INR, lower platelet count,
and lower albumin were associated with mortality.
HY’S LAW, nR HY’S LAW,
AND MELD
Hy’s law had a lower positive predictive value for
deaths primarily or partially due to DILI up to 2 years
after onset compared to nR Hy’s law (10% versus
14%). Specificities were about the same at 71% and
69%, respectively. When limited only to deaths pri-
marily due to DILI, the positive predictive values fell
to 8% for Hy’s law and 12% for nR Hy’s law. Specific-
ities did not change. Because Hy’s law and especially
MELD were put forth to predict shorter-term mortal-
ity, we also analyzed their association with DILI fatali-
ties occurring within 26 weeks due to ALF or ACLF.
On this multivariate analysis, Hy’s law was signifi-
cantly associated with early mortality primarily due to
DILI (hazard ratio [HR], 2.2, 95% confidence interval
[CI] 1.3-3.7). However, the association with nR Hy’s
law was stronger (HR, 6.2, 95% CI 3.4-11.1), and that
with MELD was stronger still. The HR per MELD
point was 1.2 (95% CI 1.1-1.2), and at various MELD
cutoffs the HRs were all over 10 (Supporting Table
S6). The C statistic for a MELD cutoff of 19 was 0.83
compared to 0.73 for nR Hy’s law and 0.60 for Hy’s
law. For the Hy’s law Cox regression analyses, ALT,
AST, and bilirubin were excluded as they are part of
Hy’s law and nR Hy’s law. INR, creatinine, and biliru-
bin were excluded in the Cox modeling for MELD.
Discussion
It is well known that DILI can lead to death or LT
(fatal outcome), but the precise role and course of
DILI in these cases is poorly defined, particularly
when fatalities occur more than 26 weeks after liver
injury. In the DILIN prospective cohort, 107 of 1,089
patients with definite, highly likely, or probable DILI
had a fatal outcome within 2 years of onset. Thus, the
all-cause fatality rate was 9.8% (Fig. 1). Fatalities
tended to be older and to have more hepatocellular
injury and more underlying chronic liver disease than
patients who survived (Table 1). Their DILI causality
assessments also tended to be less certain, probably
because the recovery, or washout, phase was truncated
by the death. The majority of the fatalities were related
to DILI, being the primary cause of death in 68
patients and a contributing cause in another 15. The
remaining 22 patients had fatal outcomes unrelated to
DILI (Fig. 1). Therefore, the DILI fatality rate
(primary or contributory) was 7.6% (83/1089). This
rate increased to 9.5% (68/712) if the denominator is
limited to those presenting with jaundice (bilirubin
2.5 mg/dL).
Comparing DILI primary, contributory, and no role
cases revealed important differences (Table 2). Primary
and contributory role cases were predominantly women
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FIG. 2. Distribution of primary causes of fatal outcome in
patients where DILI had a contributory role (gray bars) or no
role (white bars). Percentages represent proportions within each
subgroup: contributory role or no role.
*DRESS/SJS: Drug Reaction with Eosinophilia and Systemic
Symptoms/Stevens-Johnson Syndrome
**Other: 80-year-old woman with acute liver injury which con-
tributed to her death, but she had multiple medical problems and
went home on hospice.
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compared to no role cases, who were predominantly
men. Primary role cases were younger and usually fol-
lowed a course typical of ALF (50 of 68, 74%). As
expected, the majority (83%) of ALF cases presented
with a hepatocellular pattern of enzyme elevations
(high R ratios) (Table 3). This predominance of ALF
is in line with DILI being a leading cause of ALF in
the United States.(14,15) Our cases were similar to those
reported by the US ALF Group. Most were young
(<45) and women. Antimicrobials, isoniazid in partic-
ular, were the most common agents implicated; but
HDS were also prominent (Supporting Tables S2-S4).
The majority of patients with ALF were listed for LT
(74%), and most of these were transplanted (68%).
The remaining ALF patients were not listed due to
medical or psychosocial contraindications.
DILI fatality by non-ALF injury patterns has not
been well described, though a quarter of the DILIN
deaths due directly to DILI followed such non-ALF
courses. Five (7%) of the 68 primary role cases had
underlying cirrhosis and were categorized as ACLF.
For this study, we defined ACLF as a case with preex-
isting cirrhosis and DILI being the primary cause of
death or LT within 26 weeks of onset. Our data set
did not have the clinical information to determine
more recently developed acute on chronic liver failure
classifications and scores.(16,17) Of the five ACLF
cases, three were listed for transplant but only one
TABLE 3. Characteristics and Course of Liver Failure in Those Patients Who Died or Needed LT Due Primarily to DILI
Values Are Means (SD) for Continuous Variables
Primary Role Cases
(n 5 68)
Characteristic
ALF
(n 5 50)
ACLF
(n 5 5)
Chronic Liver Failure
(n 5 9)
Rapid Cholestatic
Liver Failure
(n 5 4) P
Mean age, years (SD) 48.7 (16.9) 60.1 (11.0) 51.5 (11.9) 62.3 (11.2) 0.19
Gender, female 31 (62%) 3 (60%) 6 (67%) 2 (50%) 0.96
Mean BMI, kg/m2 (SD) 29.2 (7.3) 27.3 (7.1) 28.6 (4.2) 33.0 (2.6) 0.36
Race/ethnicity
White 33 (67%) 2 (40%) 7 (78%) 4 (100%) 0.66
Black 8 (16%) 1 (20%) 2 (22%) 0 (0%)
Asian 5 (10%) 1 (20%) 0 (0%) 0 (0%)
Other or unknown 4 (6%) 1 (20%) 0 (0%) 0 (0%)
Latino 4 (8%) 0 (0%) 0 (0%) 1 (25%) 0.49
Alcohol use* 28/48 (58%) 2/5 (40%) 4 (44%) 1 (25%) 0.54
Time (days) from onset to death/LT 35 (28) 59 (50) 236 (120) 132 (91) <0.01
Liver biochemistries at onset
ALT, U/L 1,864 (1534) 451 (449) 330 (478) 395 (248) <0.01
AST, U/L 1,807 (1348) 699 (717) 279 (347) 375 (217) <0.01
Alk P U/L 240 (108) 191 (133) 226 (106) 523 (367) 0.26
Bilirubin, mg/dL 12.5 (7.2) 11.3 (7.4) 7.0 (7.3) 2.9 (2.3) 0.01
INR 2.7 (2.0) 2.3 (0.7) 1.7 (1.1) 1.1 (0.0) 0.03
R ratio† 24.4 (23.7) 4.5 (3.4) 5.5 (11.6) 3.3 (2.9) <0.01
Pattern of injury (n) (45) (5) (9) (4)
Hepatocellular 38 (84%) 3 (60%) 2 (22%) 2 (50%) <0.01
Mixed 3 (7%) 0 (0%) 1 (11%) 0 (0%)
Cholestatic 4 (9%) 2 (40%) 6 (67%) 2 (50%)
Causality category
Definite 9 (18%) 0 (0%) 0 (0%) 0 (0%) 0.33
Highly likely 19 (38%) 1 (20%) 4 (44%) 3 (75%)
Probable 22 (44%) 4 (80%) 5 (56%) 1 (25%)
Hy’s law‡ 23/45 (51.1%) 2/5 (40.0%) 0/8 (0.0%) 0/4 (0.0%) <0.01
nR Hy’s law§ 37/47 (78.7%) 3/5 (60.0%) 1/8 (12.5%) 1/4 (25.0%) <0.01
*Any alcohol consumption in the 12 months prior to DILI.
†R ratio 5 (ALT/ULN) 4 (Alk P/ULN).
‡Bilirubin 2.5 mg/dL, ALT > 3 3 ULN and Alk P <2 3 ULN at presentation.
§Bilirubin 2.5 mg/dL, and R ratio >5 at presentation (AST is substituted for ALT if AST yields greater R ratio).
Abbreviations: BMI, body mass index; SD, standard deviation.
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received a liver. The other two became too ill and were
removed from listing. The listed cases may not have
met criteria for priority listing (status 1a) due to their
underlying cirrhosis, which could explain the lower
rate of LT.
Another 9 (13%) of the 68 primary role cases had a
fatality due to chronic liver failure. These cases died or
needed LT more than 26 weeks after DILI onset.
Agents leading to chronic liver failure were varied,
with three of nine being HDS products and another
three antibiotics (Supporting Table S4). Amiodarone
and methotrexate, both known to cause an insidious
fibrosis, accounted for one each. Chronic liver injury
after DILI has been described by our group and
others.(6,7) While the definition, incidence, and signifi-
cance of chronic DILI are unclear, this study clearly
documents a small number of fatalities due to pro-
longed liver injury from DILI. These nine cases had
lower initial transaminases and R ratios compared to
those with ALF and ACLF, but no other distinguish-
ing features could be gleaned from this small number
of cases (Table 3). Larger numbers with robust pro-
spective follow-up will be needed to fully understand
these more insidious DILI deaths.
Four (6%) of the 68 primary role patients had a rapid
(<26 weeks) and progressive cholestatic injury. DILI
causing such severe cholestatic injury with ductopenia
has been described.(18-20) These 4 all died or required
transplant within 26 weeks of DILI onset. They tended
to be older, 3 being over 60 years old. Two had a chole-
static pattern of injury from onset to demise, while 2
presented with a hepatocellular pattern of injury (R
ratio just over 5) that quickly transitioned to cholestatic.
The R ratios were <1 in all 4 at time of death or trans-
plant. One patient underwent LT, and the explant his-
tology showed absence of bile ducts. The remaining 3
had medical or psychosocial contraindications to trans-
plantation. Liver biopsies in these 3 did not show duc-
topenia, but biopsies may have been obtained too early
to capture vanishing bile duct histology. Autopsy liver
tissues were not available for these cases.
DILI as a contributing cause of fatality has been
poorly defined and rarely reported. Yet, such a contrib-
utory role in deaths may be an important part of the
DILI disease burden. In this series, DILI contributed
to death by worsening of an underlying liver disease
(20%) or by contributing to a non-liver-related death
such as DRESS/Steven-Johnson syndrome, sepsis, or
malignancy (20% each) (Fig. 2). In the 3 patients with
cancer, DILI significantly limited subsequent thera-
peutic options. In one case, evaluation of liver injury
included an endoscopic retrograde cholangiopancrea-
tography that was complicated by a fatal duodenal
perforation.
TABLE 4. Variables Significantly Associated With Fatalities Due Primarily (Primary Role) or Partially (Contributory Role) to
DILI on Univariate and Multivariate Analyses
Cox Regression
Univariate Multivariate
Variable HR (95% CI) P HR (95% CI) P
Race
Caucasian Referent -
Black 1.5 (0.8-2.8) 0.16
Asian 3.4 (1.6-7.5) <0.01
Other 1.1 (0.4-3.0) 0.89
BMI (kg/m2) 1.04 (1.0-1.1) 0.01
Diabetes 2.3 (1.5-3.5) <0.01
Heart failure 3.3 (1.2-9.0) 0.02
Chronic liver disease 1.9 (1.1-3.3) 0.03
Neutropenia 3.6 (1.1-11.4) <0.01
Steven-Johnson syndrome/DRESS 5.0 (1.2-20.5) 0.02
INR at onset 6 14 days 1.5 (1.4-1.6) <0.01 1.6 (1.4-1.7) <0.01
ALT (per 50 U/L) 1.01 (1.0-1.01) <0.01
Total bilirubin (mg/dL) 1.1 (1.0-1.1) <0.01 1.1 (1.0-1.1) <0.01
Hemoglobin (g/dL) 0.9 (0.8-1.0) 0.05
White blood cells (109/L) 1.1 (1.0-1.1) <0.01 1.06 (1.02-1.10) <0.01
Platelets (1010/L) 0.99 (0.99-0.99) <0.01 0.99 (0.99-0.99) <0.01
Albumin (g/dL) 0.4 (0.3-0.5) <0.01 0.4 (0.3-0.6) <0.01
Corticosteroids given 3.3 (2.2-5.1) <0.01
Abbreviation: BMI, body mass index.
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While categorizing DILI as a primary versus con-
tributory cause of death was occasionally difficult,
assigning it as having no role was often straightfor-
ward. Many of these deaths occurred well after DILI
had resolved. The majority of these cases were due to
progression of a malignancy (Fig. 2). Certain comor-
bidities could forebode poor outcome even after appar-
ent liver recovery. Identifying such factors by a
comorbidity index (e.g., Charleson, Elixhauser) would
be useful, but unfortunately the DILIN does not cap-
ture the detailed information on comorbidities needed
to complete such indices.
After we had categorized all fatalities, we identified
variables associated with DILI-related deaths (primary
and contributory role cases). The current analysis dif-
fers from our prior studies examining DILI fatalities at
just 26 weeks.(2,5) In this study, we included fatalities
up to 2 years after DILI onset. Also, categorization of
DILI’s role in the fatality was done using a systematic
approach and by a subcommittee of DILIN investi-
gators, who used a new contributory role category and
subcategorization of primary role cases by pattern of
liver demise.
Variables independently associated with overall
DILI-related fatality were all plausible. Higher INR,
higher bilirubin, and lower albumin all reflect more
severe liver dysfunction at onset. Higher white blood
cell count could reflect more immune-mediated injury
or concurrent infection (i.e., sepsis). The association of
mortality with lower platelets is in line with a recent
study identifying thrombocytopenia with poor out-
come for ALF in general.(21) The lower platelet count
may reflect multiorgan failure, sepsis, or disseminated
intervascular coagulation. Interestingly, preexisting
chronic liver disease was not associated with mortality
on multivariate analysis, though it was on univariate.
This finding is similar to our two prior studies that
found an association between chronic liver disease and
short-term mortality on univariate analysis only. Nei-
ther study detected an independent association.(2,5)
With the inclusion of deaths up to 2 years later and
DILI contributory role deaths, we thought this variable
might now be independently associated. The persistent
lack of association could be a result of too few patients
to detect a smaller increased risk (underpowered), or
the risk may apply only to more advanced liver disease.
Our definition of prior chronic liver disease did not
specify degree of fibrosis or liver dysfunction.
We show an incremental improvement in Hy’s law
by use of the modified nR form.(8) For deaths due pri-
marily or partially to DILI, Hy’s law had a 10%
positive predictive value, precisely in line with Dr.
Zimmerman’s original suggestion.(22) However, the
nR modification of Hy’s law yielded a higher positive
predictive value at 14%. The difference lay primarily in
the ability to identify those who would die of DILI-
related ALF: 79% of ALF fatalities met nR Hy’s law
versus only 52% meeting standard Hy’s law (Table 3).
The Alk P <2 3 ULN criteria explained all the ALF
deaths which met nR Hy’s law but not standard Hy’s
law. In Dr. Zimmerman’s text, the limit for Alk P was
<1 to 3 3 ULN, but a cutoff of 2 3 ULN is typically
used.(5,8,22) The ALF fatalities not meeting Hy’s law
had Alk P/ULN ratios ranging from 2.0 to 3.5, low
enough to yield an R ratio >5 but too high for stan-
dard Hy’s law. Thus, the use of nR Hy’s law over the
traditional Hy’s law as a positive predictor of increased
risk of death due to DILI may be warranted in clinical
practice and drug development.
Compared to Hy’s law or nR Hy’s law, MELD was
a better predictor of acute DILI deaths (<26 weeks)
by ALF and ACLF (Supporting Table S6). The HR
for a MELD >19 was 35.6 with a C statistic of 0.83,
compared to an HR of 2.2 and a C statistic of 0.60 for
Hy’s law and an HR of 6.2 and a C statistic of 0.73 for
nR Hy’s law. MELD probably had the advantage of
often being calculated later because INR was not
always obtained with the first set of elevated liver
enzymes. More importantly, Hy’s law and MELD
were put forth for different purposes. Dr. Zimmerman
shared his astute observation as a warning to clinicians
to be vigilant of a severe outcome when hepatocellular
DILI meets certain ALT, Alk P, and bilirubin criteria.
As such, it was merely a positive predictive value set
low at 10% to cast a wide net for patients needing close
follow-up. On the other hand, MELD was based on
multivariate modeling to predict mortality risk sur-
rounding therapeutic interventions, first transjugular
intrahepatic portosystemic shunt and then transplant,
where predictive precision is the goal, and not just a
low threshold positive predictive value.
In this systematic examination of fatalities prospec-
tively followed in the DILIN, 7.6% of patients died
primarily or partially from the DILI within 2 years of
onset. When DILI was the primary cause of death,
typical ALF accounted for most fatalities, but one
quarter had non-ALF courses including acute on
chronic, chronic, and progressive cholestatic liver fail-
ure. When DILI contributed to death, most fatalities
were due to sepsis, malignancy, DRESS/Steven-John-
son syndrome, or worsening preexisting chronic liver
disease. However, preexisting liver disease was not
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independently associated with fatality from DILI. The
nR modification of Hy’s law improved the positive
predictive value for those at risk of death from acute
hepatocellular injury by accepting moderately higher
Alk P elevations into the criteria. The nR modification
also has a stronger the association with deaths within
26 weeks directly related to DILI, but neither outper-
formed MELD in predictive value.
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